Policies, Standards, and Guidelines Guidelines on Breast Ultrasound Examination and Reporting Approved by Council June 2018
Approved: June 2018 Guidelines on Breast Ultrasound Examination and Reporting Summary Ultrasound practitioners conducting breast ultrasound scans should be fully trained in ultrasound with a thorough understanding of the principles, procedures, technology and reporting involved. Sonographers must have appropriate industry accreditation. It is expected that the ultrasound practitioner will follow a reasonable course of action utilising appropriate practice based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. Images and documentation of all important findings should be recorded in a retrievable and reviewable image storage format. Purpose These Guidelines have been developed to assist practitioners in the performance and reporting of breast ultrasound. These Guidelines supersede the D4 Statement on Breast Ultrasound Examination and Reporting: Originally approved/effective: June 1990 Reaffirmed: May 1997 Revised: September 1999, March 2012. Scope/Applicability These guidelines are applicable to all ultrasound practitioners. Background Breast cancer is now the most common cancer affecting Australian women. Finding cancer at an early stage increases the chances of successful treatment and improved survival. It is not appropriate to confirm or exclude diagnosis of breast cancer without undertaking a triple test which includes taking a personal history and a clinical breast examination, imaging tests (mammogram and/or ultrasound and/or MRI) and a biopsy to remove cells or tissue for examination. Most women show no signs of cancer on any of the tests. The small number of women who show possible signs of cancer on one or more of the tests may be advised to see a surgeon for further tests or treatment (14,15 17). The role of ultrasound in breast cancer screening remains unresolved. As there is a higher biopsy rate due to higher false positives compared to mammography, ultrasound is not recommended as a primary screening tool in the general population. Ultrasound is not recommended in lieu of MRI in the very high risk patient. Recent studies have shown that ultrasound may improve the detection of early breast cancer in women with an increased risk who are not able to access MRI. Breast thermography is not recommended in the detection or management of breast cancer (16,17). Page 2 of 7 05/18
Guideline 1 Pre-Performance of Ultrasound Requirement Procedure #1 Indications for examination. 1. For the evaluation and characterisation of a clinical abnormality. 2. For the evaluation and characterisation of an abnormality demonstrated on other imaging eg mammography, MRI, CT. 3. For guidance of interventional procedures (e.g. biopsy, clip placement, hook wire insertion, drainage of abscess etc). 4. For treatment planning and evaluation of impact of therapy (tumour size reduction/ no change/ increased size or no response to therapy). 5. For post-operative assessment. 6. For the assessment of implants, in particular extracapsular rupture, peri-prosthetic fluid collections. Ultrasound is not recommended for assessment of intra-capsular rupture, where MRI is the gold standard 7. For the initial evaluation of palpable masses in the young (<30 years of age), lactating and pregnant women. 8. As an adjunct to mammography in women with dense breasts (3,4,5) and in high risk women (for example in women with a prior history of breast cancer) 9. Assessment of nodal spread in the axilla Procedure #2 Correlation. 1. Previous related imaging should be reviewed prior to the ultrasound examination. 2. The number and position of both clinical and mammographic/mri lesions should be known prior to scanning. 3. The Sonographer/Sonologist must correlate any palpable abnormality to the ultrasound findings 4. Knowledge of mammography imaging and positioning and MRI positioning is required to enable accurate imaging correlation to the ultrasound findings. 5. When lesions demonstrated on MRI are identified on second look ultrasound, it is mandatory that a clip be placed following biopsy in the lesion to confirm concordance of the ultrasound lesion with the initial MRI lesion. Guideline 2 Equipment Requirement 1. A linear array transducer should be used at the highest frequency capable to adequately evaluate the breast and to penetrate the depth and density of the breast. 2. A transducer with a broad range of operating frequencies is desirable to evaluate both superficial lesions and the dense breast. The transducer must at least operate at 7.5 MHz. An acoustic standoff pad may be useful for very superficial lesions. Guideline 3 The Examination Requirement 1. Patient positioning is crucial to the effectiveness of the scan the breast tissue should be Page 3 of 7 05/18
spread out as evenly as possible over the chest wall. Variations of supine and semi-oblique with the arm raised should be considered. It may be necessary to place a cushion under the patient s shoulder on the side being scanned. For some lesions initially identified on a mammogram, it may sometimes be helpful to scan the patient erect to emulate the craniocaudal position. For lesions initially identified on MRI scans it may necessary to recreate the MRI prone position. 2. The breast should be scanned in a uniform and comprehensive fashion, including the axillary tail. Scanning technique may be in the anti-radial, radial, longitudinal or transverse planes. Procedure #1 Imaging Requirements & Measurements. 1. The axilla should be fully examined; lymph nodes should be characterised when identified: cortical thickness and hilum appearance. 2. The retroareolar region should be examined. 3. All masses and areas of concern should be scanned in at least 2 orthogonal planes. Image optimization including the use of harmonics, colour Doppler and elastography may help to characterize the lesion. 4. Measurements should be taken to accurately represent the size of the lesion; with the longest length and depth measured in one plane and then the width at ninety degrees to this, the extent of multi-focal disease is to be noted. 5. Palpable or clinical areas of concern should be carefully assessed and correlated to the ultrasound findings. Procedure #2 Documentation. 1. The breast should be visualized as a clock face with representative images taken. 2. As a minimum it is recommended that (a) images always be documented at 12,3,6 and 9 o clock in a radial plane, with the distance of the lesion from the nipple measured in cm (b) images of the axilla and retroareolar region should be recorded in the normal breast. (c) the position of the image should be included in the written annotation (i.e. radial, anti-radial, transverse, longitudinal). (d) the use of positional or body markers is unsuitable and not supported. 3. Palpable or clinical areas of concern should be documented with ROI region or AOI area of interest. Note should be made as to what anatomy/pathology correlates to the indicated region/area of interest. 4. All areas of clinical or ultrasound interest should be noted and lesion descriptors included. 5. The positions of all lesions should be accurately documented, and the distance from the centre of the nipple recorded, on the clock face. Procedure #3 Mass Characterisation. 1. Masses should be characterised with respect to the Stavros benign and malignant criteria (7) and descriptions provided. 2. Assess: (a) Size in 3 planes including maximum diameter in mm (b) Shape round, ellipsoid, septated, irregular, height vs width ratio, orientation to skin (c) Internal contents cystic, solid, mixed, blood flow Page 4 of 7 05/18
(d) Margins smooth, lobulated (number, gentle, microlobulations), ill-defined, angular, spiculated, branch extension, duct extension (e) Echogeniticity anechoic, isoechoic, hypoechoic, hyperechoic, mixed (f) Texture homogeneous, heterogeneous (g) Calcifications large, fine (h) Posterior sound transmission enhancement, shadowing, no change (i) Capsular thickness thin, complete, incomplete, thick, irregular (j) Effect on surrounding structures distortion, disrupts, invades. (k) Comparison with previous imaging and comment on new lesions, change in size or stability of lesions should be stated as this is very important sign and will affect ongoing management and/or surveillance. Guideline 4 Reports Requirement 1 1. Uniformity of reporting is essential to ensure accurate lesion follow-up, localization for procedures and comparison with other imaging modalities. 2. Images should be annotated in reference to the clock face where applicable. 3. In addition, images of masses/regions of interest should be annotated as follows: (a) orientation of the transducer (e.g. radial, antiradial, longitudinal, transverse) (b) distance of lesion from the central nipple in centimetres (positional markers are not to be used). 4. Use of the standardized breast imaging report and classification system (6) is encouraged. 5. Imaging classification (13) : (a) No significant imaging abnormality detected (b) Benign findings (c) Indeterminate/equivocal lesion (d) Suspicious features of malignancy (e) Malignant. The RANZCR Breast Imaging Advisory Committee has recommended that BIRADS categories be used for the classification of breast lesions in preference to the older breast screen category classification to make the process uniform across all imaging modalities. Related/Supporting documents The following documents are required to give effect to this guideline: 1. ASUM Guidelines for the Reprocessing of Ultrasound Transducers. Supporting information/references The following documents inform this guideline: 1. American College Radiology. Practice Parameter for the Performance of a Breast Ultrasound Examination; Revised 2016 (Resolution 38). 2. American College Radiology Imaging Network. ACRIN 6666: Screening Breast Ultrasound in High-Risk Women (Partial Protocol), 9 November 2007. 3. Cancer Australia. Tests for breast cancer. https://breastcancer.canceraustralia.gov.au/diagnosis/tests, 20 October 2017. Page 5 of 7 05/18
4. Cancer Australia. Influencing best practice in breast cancer. Key appropriate and inappropriate breast cancer practices, Cancer Australia, Surry Hills, 2016. 5. Kaplan, SS. Clinical utility of bilateral whole-breast ultrasound in the evaluation of women with dense breast. Radiology 2001; 221:641-649. 6. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 2002; 225:165-175. 7. Morris KT, Pommier RF, Morris A, et al. Usefulness of the triple test score for palpable breast masses; discussion 1012-3. Archives of Surgery 2001; 136(9):1008-12. 8. National Breast Cancer Centre. Synoptic Breast Imaging Report Including Imaging Classification (1 5); April 2007, RANZCR, Sept 2016. 9. National Breast and Ovarian Cancer Centre. Investigation of a new breast symptom, a guide for general practitioners, Surry Hills, NSW, 2006. 10. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2015; 26 Suppl 5:v8-30. 11. Statement of Principles: Breast Cancer Imaging in Australia, 9 November 2016. 12. Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA. Solid Breast Nodules: Use of sonography to distinguish between benign and malignant lesions. Radiology 1995; 196:123-134. 13. ACR: ACR BI-RADS Atlas 5th Edition, 2013. 14. Australian Government Cancer Australia. The investigation of a new breast symptom. A guide for General Practitioners, 2017. 15. Australian Government Department of Health. BreastScreen Australia. Policy, 2018. 16. Australian Government Cancer Australia. Statement on use of thermography to detect breast cancer, 2010. 17. Mann,R.M., Kuhl, C.K., Kinkel, K. & Boetes, C. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 2008; 18: 1307-1318. Definitions The following definitions are relevant to this guideline. Term Appropriate practice Definition one that provides patient benefit; is effective (based on valid evidence, including evidence of benefit); efficient (cost-effective); equitable and consistent with the ethical principles and preferences of the individual patient Contact ASUM Standards of Policy Officer Email: asum@asum.com.au Review This guideline will be reviewed and evaluated as required to ensure relevance and currency. Version Effective from Effective to Amendment(s) Published in Page 6 of 7 05/18
1.0 June 2018 present Original July 2018 The review table indicates previous versions of the guideline and any significant changes. Approval This guideline has been approved and issued by the ASUM Council. Approval by ASUM Council Approval date June 2018 Published date July 2018 Page 7 of 7 05/18